Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
26.50
Nov 20 • 3:59 PM ET Dollar change-0.82 Percentage change(-2.98%)
Aftermarket Close
26.50
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
1.35B
Enterprise Value
1.35B
Income
-61.66M
Sales
9.75M
Book/sh
-0.75
Cash/sh
2.49
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
97
IPO
Dec 11, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
138.48
P/B
-
P/C
10.65
P/FCF
-
EV/EBITDA
-
EV/Sales
137.98
Quick Ratio
1.44
Current Ratio
1.44
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-1.27
EPS next Y
-0.22
EPS next Q
-
EPS this Y
-5.10%
EPS next Y
63.86%
EPS next 5Y
-
EPS past 3/5Y
30.98% 18.47%
Sales past 3/5Y
- 257.86%
EPS Y/Y TTM
-58.83%
Sales Y/Y TTM
-
EPS Q/Q
-559.84%
Sales Q/Q
-84.39%
Insider Own
18.09%
Insider Trans
0.00%
Inst Own
1.43%
Inst Trans
1.18%
ROA
-61.74%
ROE
-
ROIC
-131.02%
Gross Margin
-
Oper. Margin
-392.06%
Profit Margin
-632.55%
SMA20
-13.07%
SMA50
-9.58%
SMA200
-23.11%
Trades
Shs Outstand
50.80M
Shs Float
41.73M
52W High
57.14 -53.62%
52W Low
19.14 38.45%
Volatility
10.52% 7.20%
ATR (14)
2.37
RSI (14)
40.17
Beta
0.92
Rel Volume
0.85
Avg Volume
147.73K
Volume
125,290
Perf Week
-13.55%
Perf Month
-9.22%
Perf Quarter
-33.18%
Perf Half Y
-35.38%
Perf YTD
14.62%
Perf Year
30.03%
Perf 3Y
333.01%
Perf 5Y
185.87%
Perf 10Y
-
Prev Close
27.32
Price
26.50
Change %
-2.98%
Consensus
Strong Buy
Avg. Price Target
$55.66
Implied Upside
+110.0%
Analysts4incl. previous ratings
Rating Distribution4 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 15, 2026Resumed
GGuggenheim
Buy$64+141.5%
Feb 06, 2026Initiated
TD logoTTD Cowen
Buy
Aug 28, 2024Initiated
GGuggenheim
Buy$12-54.7%
Dec 08, 2023Initiated
LLeerink Partners
Outperform$11-58.5%
Jan 06, 2021Initiated
EVR logoEEvercore ISI
Outperform
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. Its technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. The company was founded by Laurent Levy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.
Co-FounderDr. Laurent Levy Ph.D.
Chief People Officer & Member of Executive BoardMs. Anne-Juliette Hermant M.A.
Chief Medical Officer & Member of Executive BoardDr. Louis Kayitalire M.D.
Co-FounderMr. Earl J. Bergey Ph.d.
CFO & Member of Executive BoardMr. Arnd Christ MBA